At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 12 enrolled
Drug / intervention
Brigatinib +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-Label, Randomized, Single-Dose, 2-Period, Crossover Study to Evaluate the Relative Bioavailability of Brigatinib Administered as an Oral Solution Versus an Immediate-Release Tablet in Adult Healthy Subjects
In Brief
A Phase 1 clinical trial evaluating Brigatinib for Healthy Volunteers. Completed, enrolled 12 participants across 1 site.
Detailed Summary
The main aim of this study is to compare the amount of brigatinib in the blood of healthy adults after they have swallowed one dose either as a solution or as a tablet.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedNov 2023
Enrollment StartDec 2023
Primary CompletionFeb 2024
TodayJul 2026
First PostedNov 15, 2023
Enrollment StartDec 20, 2023
Primary CompletionFeb 17, 2024
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 2.6 years ago
Interventions
Brigatinibdrug
Brigatinib oral solution
Brigatinibdrug
Brigatinib tablet